Jakarta - Delayed Quote IDR
PT Millennium Pharmacon International Tbk (SDPC.JK)
129.00
-1.00
(-0.77%)
At close: May 23 at 4:10:40 PM GMT+7
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
3,923,318,897.08
3,916,863,878.53
3,363,517,807.83
3,200,833,096.42
2,988,848,566.33
Cost of Revenue
3,582,601,039.64
3,582,486,836.95
3,071,171,859.79
2,931,198,452.41
2,747,094,995.80
Gross Profit
340,717,857.43
334,377,041.58
292,345,948.05
269,634,644.01
241,753,570.54
Operating Expense
239,957,777.44
237,943,333
186,948,370.89
191,737,683.77
185,776,866.62
Operating Income
100,760,079.99
96,433,708.58
105,397,577.16
77,896,960.24
55,976,703.92
Net Non Operating Interest Income Expense
-70,594,699.09
-68,732,405.99
-57,436,809.03
-37,497,964.84
-39,814,268.38
Pretax Income
30,165,380.91
27,701,302.59
47,960,768.13
36,464,134.24
17,922,516.59
Tax Provision
10,009,142.97
10,787,170.47
14,879,566.29
12,000,079.37
8,351,281
Net Income Common Stockholders
20,162,855.37
16,928,878.94
33,087,528.53
24,464,054.88
9,571,235.58
Diluted NI Available to Com Stockholders
20,162,855.37
16,928,878.94
33,087,528.53
24,464,054.88
9,571,235.58
Basic EPS
15.83
13.29
25.97
19.20
7.51
Diluted EPS
15.83
13.29
25.97
19.20
7.51
Basic Average Shares
1,274,000
1,274,000
1,274,000
1,274,000
1,274,000
Diluted Average Shares
1,274,000
1,274,000
1,274,000
1,274,000
1,274,000
Total Operating Income as Reported
100,760,079.99
96,433,708.58
105,397,577.16
73,962,099.08
57,736,784.96
Rent Expense Supplemental
2,865,249.67
3,140,552.88
2,972,229.12
3,115,230.73
2,965,424.71
Total Expenses
3,822,558,817.08
3,820,430,169.95
3,258,120,230.68
3,122,936,136.18
2,932,871,862.41
Net Income from Continuing & Discontinued Operation
20,162,855.37
16,928,878.94
33,087,528.53
24,464,054.88
9,571,235.58
Normalized Income
20,162,855.37
16,928,878.94
33,087,528.53
27,103,982.06
8,198,372.37
Interest Income
63,286.34
59,006.19
139,719.01
984,048.36
80,141.52
Interest Expense
70,657,985.43
68,791,412.18
57,576,528.04
38,482,013.20
39,894,409.89
Net Interest Income
-70,594,699.09
-68,732,405.99
-57,436,809.03
-37,497,964.84
-39,814,268.38
EBIT
100,823,366.34
96,492,714.77
105,537,296.17
74,946,147.44
57,816,926.48
EBITDA
124,320,231.97
120,064,591.52
124,507,869.15
91,477,228.94
73,602,422.71
Reconciled Cost of Revenue
3,582,601,039.64
3,582,486,836.95
3,071,171,859.79
2,931,198,452.41
2,747,094,995.80
Reconciled Depreciation
23,496,865.63
23,571,876.75
18,970,572.98
16,531,081.50
15,785,496.24
Net Income from Continuing Operation Net Minority Interest
20,162,855.37
16,928,878.94
33,087,528.53
24,464,054.88
9,571,235.58
Total Unusual Items Excluding Goodwill
--
--
0
-3,934,861.15
1,760,081.05
Total Unusual Items
--
--
0
-3,934,861.15
1,760,081.05
Normalized EBITDA
124,320,231.97
120,064,591.52
124,507,869.15
95,412,090.10
71,842,341.67
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
-1,294,933.97
387,217.83
12/31/2021 - 9/3/2001
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade